North East and North Cumbria
ICS Formulary
 
back
8 Malignant disease and immunosuppression
08-02-04 Dimethyl fumarate

Dimethyl fumarate Tecfidera®
Formulary

  • Approved as a option for treating adults with active relapsing-remitting multiple sclerosis that isn’t highly active or rapidly evolving severe relapsing-remitting multiple sclerosis NICE and NHS England Commissioning Policy. 

Link  Disease Modifying Therapies for Patients with Multiple Sclerosis (MS)
Link  MHRA Drug safety Update (April 2016): Dimethyl fumarate (Tecfidera): updated advice on risk of progressive multifocal leukoencephalopathy.
Link  MHRA Drug Safety Update (January 2021): Dimethyl fumarate (Tecfidera): updated advice on the risk of progressive multifocal leukoencephalopathy (PML) associated with mild lymphopenia
Link  MHRA Drug Safety Update (March 2015): Dimethyl fumarate (Tecfidera): fatal PML in an MS patient with severe, prolonged lymphopenia
Link  NICE TA320: Dimethyl fumarate for multiple sclerosis

Red View adult BNF  View SPC online  View childrens BNF  HCD